一心堂(002727.SZ):2022年度擬向相關銀行申請集團授信總額為41.4億元
格隆匯11月26日丨一心堂(002727.SZ)公佈,公司第五屆董事會第十二次會議召開,審議通過了《關於公司及子公司向相關銀行申請綜合授信額度的議案》。該議案尚需提交公司股東大會審議。
因經營需要,2022年度一心堂藥業集團股份有限公司及子公司向相關銀行申請集團授信,總額為41.4億元,具體額度在不超41.4億元的金額上限內以銀行授信為準,在一年範圍內以銀行授信為準。
綜合授信內容包括但不限於流動資金貸款、項目資金貸款、銀行承兑匯票、保函、保理、開立信用證、押匯、國內貿易融資業務、票據貼現、中票、短融、超短融等綜合授信業務,在額度內循環使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.